Biologica Technologies announced the official launch of its adipose filler, Allofill, during this weekend’s American Society of Plastic Surgeons (ASPS) – Plastic Surgery The Meeting in Los Angeles, CA.  Allofill is the first product of its kind; a ready to use, ‘off the shelf’, adipose-derived injectable filler that works with the body to provide an all-natural tissue scaffold with native growth factors.  Allofill retains the native extracellular matrix (ECM) components of allograft-derived adipose tissue and over time will be remodeled into a patient’s own soft tissue.

“We are excited to bring this first of its kind technology to market and provide plastic surgeons a new, unique option as compared to autologous fat transfer (AFT) and the various hyaluronic acid (HA) fillers available on the market,” stated Amit Govil, president and founder of Biologica Technologies.

Biologica’s exclusive tissue processing methods have the ability to harvest various growth factors found within allogeneic adipose tissue and bind them to a collagen scaffold.  The result is a unique allograft product with higher growth factors than a standard autologous fat transfer and more natural than an HA, or similar, dermal filler.

About Biologica Technologies

Founded in 2015, Biologica Technologies is a privately-held company fully dedicated to improving patients’ lives and the health care providers’ experience through innovative biologic solutions. The first aesthetic product, Allofill, is an adipose-derived filler containing naturally occurring growth factors which can be used to fill soft-tissue defects as a noninvasive alternative to autologous fat grafting.  Additional products to follow include an acellular dermal matrix (ADM) and cartilage matrix, both processed via Biologica’s exclusive technology and containing naturally occurring growth factors. The company is headquartered in Carlsbad, CA.